The Gene Analysis Shared Resource (GASR) provides Mayo Clinic Cancer Center researchers efficient, high-quality, cost-effective access to state-of-the-art genomics technologies for studying gene structure and function. Since 2003, the GASR components have been working in a coordinated fashion to provide technical expertise, instrumentation, and coordinated support for DMA sequencing, gene expression profiling, and genotyping. Support for gene expression regulation through RNAi analysis was added in 2007. The services provided by the facility include large-scale, full-service re-sequencing analysis using ABI 3730x1 sequencers, plus comprehensive genotyping and gene transcript analysis using Affymetrix Genechip? technology and Illumina BeadChips. Recent additions to our capabilities include Agilent array CGH and miRNA analysis as well as NextGen sequencing on an Illumina 1G Genome Analyzer Since the last competitive grant renewal, more than 130 Cancer Center members have used the services offered by the GASR and Cancer Center projects account for about two-thirds of all the activity in the GASR. The primary goals of the GASR are to bring cutting edge genomic technologies to Mayo researchers and to do so at an affordable price. This includes, but is not limited to: i. maintaining solid expertise in the use of well-defined commercial platforms for genomic analysis and translating this knowledge into high quality data for Cancer Center members, ii. continued exploration, validation, and implementation of new technologies which will advance the capabilities of the GASR to provide cutting edge genomic assays, iii. enhancement of the utility of archived and fresh clinical samples by developing methodologies which allow for the use of very small amounts of ribonucleic acid from formalin fixed, paraffin embedded (FFPE) and laser-captured microdissected tissues, iv. exploration of new technologies, such as "next generation sequencing," and miRNA profiling based on input from users of the GASR for continuous improvement. In addition, we will continue to work closely with bioinformatics and biostatistics to insure seamless interpretation of the data generated through GASR services.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43

Showing the most recent 10 out of 340 publications